|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In NHS and HPFS, the association of PTGS2 (COX-2) expression with colorectal cancer-specific survival differed by BRAF mutation status (P<sub>interaction</sub> = 0.0005); compared with PTGS2 (COX-2)-negative/low carcinomas, the multivariable-adjusted hazard ratios for PTGS2 (COX-2)-high carcinomas were 2.44 (95% confidence interval, 1.39-4.28) in BRAF-mutated cases and 0.82 (95% confidence interval, 0.65-1.04) in BRAF-wild-type cases.
|
30826660 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The molecular diagnosis based only on genetic alterations can lead to treatments with unpredictable responses, depending on the tumour location, such as the tumour response in melanomas versus colon carcinomas with BRAF mutations.
|
30667539 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In 3D cultures, Caco‑2 cells transfected with mutated KRAS or BRAF formed multicellular structures analogous to anoikis‑resistant subpopulations in actual carcinomas, and serve as an in vitro model for anoikis resistance.
|
31545494 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
LLS carcinomas were diagnosed at a mean age of 65 years (vs. 44 years in LS, p < 0.001), had a proximal to distal ratio of 1:1, and all were BRAF V600E-negative.
|
30575961 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF inhibitors showed activity in BRAF V600E mutated cholangiocarcinomas and pancreatic carcinomas in non-first line settings.
|
31221175 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CUP adenocarcinomas and poorly differentiated carcinomas harboured the highest frequency of variants in genes involved in signal transduction pathways (e.g.MET, EGFR, HRAS, KRAS, and BRAF).
|
29973234 |
2018 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recently, BRAF gene rearrangements were identified in over 20% of acinar-type neoplasms, which included both pure acinar cell carcinomas and mixed carcinomas with acinar differentiation, using next-generation sequencing-based platforms, providing a potential therapeutic target for patients with these neoplasms.
|
28884748 |
2018 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<i>BRAF V600E</i> mutation associated with papillary (94/139, 68%), poorly differentiated (4/39, 10%), and anaplastic (3/12, 25%) carcinomas.
|
29695638 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with colorectal adenocarcinomas, mixed adenoneuroendocrine carcinomas were more frequently BRAF (37%; P=0.006), and less frequently KRAS (21%; P=0.043) and APC (16%; P=0.001) mutated.
|
28059096 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hierarchical clustering isolated three relevant clusters: (i) cluster of microsatellite stable mucinous adenocarcinomas (54%) with KRAS mutation, and frequent MGMT changes, more frequently located in the left colon, often associated with contiguous precursor adenoma; (ii) cluster of BRAF-mutated mucinous adenocarcinomas (28%) with either microsatellite instability-high or microsatellite stable status, occurring in elderly female patients, nearly all located in the right colon, having the signature of serrated pathway of carcinomas; and (iii) a heterogeneous cluster of microsatellite instability-high mucinous carcinomas (18%), including inherited colorectal carcinomas, displaying a high-grade histological pattern.
|
28429715 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Few authors demonstrated that some architectural and specific cellular findings (i.e. polygonal eosinophilic cells defined as "plump cells" and sickle-shaped nuclei) are able to predict BRAF V600E mutation in both cytological and histological samples of papillary thyroid carcinoma (PTC) as well as in other carcinomas.
|
27738305 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We evaluated 60 follicular adenomas (FA), 29 minimally invasive follicular carcinomas (MIFTC), 82 papillary carcinomas, follicular variant (FVPTC), and 16 noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFT-P) for the molecular status of BRAF, H-, N-, K-RAS, and TERT and correlated it with clinic-pathological parameters of tumors.
|
28975450 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To determine the association of DNA mismatch repair (MMR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy.
|
28006055 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Moreover, BRAF mutated colonic carcinomas have distinct clinical and histopathologic features.
|
25710585 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF fusions included 3% (14/531) of melanomas; 2% (15/701) of gliomas; 1.0% (3/294) of thyroid cancers; 0.3% (3/1,062) pancreatic carcinomas; 0.2% (8/4,013) nonsmall-cell lung cancers and 0.2% (4/2,154) of colorectal cancers, and were enriched in pilocytic (30%) vs. nonpilocytic gliomas (1%; p < 0.0001), Spitzoid (75%) vs. nonSpitzoid melanomas (1%; p = 0.0001), acinar (67%) vs. nonacinar pancreatic cancers (<1%; p < 0.0001) and papillary (3%) vs. nonpapillary thyroid cancers (0%; p < 0.03).
|
26314551 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The vast majority of the BRAF V600E mutations were found in cerebral metastases of malignant melanomas and carcinomas (29/135, 22 %), with false-positive staining found in four breast cancer cases and two non-small-cell lung carcinoma (NSCLC) samples.
|
27350555 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
High-grade serous carcinoma is associated with TP53 mutations, whereas low-grade serous carcinomas are associated with BRAF and KRAS mutations.
|
26892153 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Whereas, BRAF-mutated carcinomas more frequently demonstrated histologic features such as proximal location (60.9% vs 20.9%, p = 0.001), low-grade histology (43.5% vs 18.0%, p = 0.005), mucinous differentiation (69.6% vs 25.9%, p = 0.001) and deficient MMR (dMMR) (21.7% vs 7.6%, p = 0.03).
|
25929517 |
2015 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, it has been shown that tumor driver mutations in BRAF, and RET rearrangements - altogether termed "BRAF-like" carcinomas - have a very similar expression pattern and constitute a distinct category.
|
26030480 |
2015 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
While risk of relapse was not different per side, SAR was much poorer for proximal than for distal stage III carcinomas in a multivariable model including BRAF mutation status [N = 285; HR 1.95, 95% CI (1.6-2.4), P < 0.001].
|
25057166 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An identical c.1799T>A single nucleotide substitution leading to the BRAF V600E mutation was identified in 27 of 113 (24%) colon carcinomas.
|
24832158 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Ninety-one (6.4%) carcinomas were mismatch repair-proficient and BRAFV600E mutant, and these tumors demonstrated a significantly worse 5-year survival of 49.7% compared with mismatch repair-proficient BRAF wild type (74.1% of tumors, 65.4% survival), mismatch repair-deficient BRAFV600E mutant (12.9% of tumors, 70.1% survival), and mismatch repair-deficient BRAF wild type (6.6% of tumors, 73.6% survival).
|
24157612 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Notwithstanding their attractiveness as targets for molecular therapy, limited information is available regarding BRAF-mutated lung carcinomas.
|
24297085 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
|
24372748 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
BRAF or RET-PTC was detected exclusively in malignant lesions but not in follicular carcinomas (P < .001).
|
24830619 |
2014 |